Caisse DE Depot ET Placement DU Quebec decreased its position in Zoetis Inc (NYSE:ZTS) by 12.3% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 50,537 shares of the company’s stock after selling 7,100 shares during the period. Caisse DE Depot ET Placement DU Quebec’s holdings in Zoetis were worth $3,641,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Invictus RG purchased a new position in Zoetis in the fourth quarter valued at $401,000. 12th Street Asset Management Company LLC increased its holdings in Zoetis by 5.4% in the fourth quarter. 12th Street Asset Management Company LLC now owns 183,595 shares of the company’s stock valued at $13,227,000 after buying an additional 9,419 shares in the last quarter. MML Investors Services LLC increased its holdings in Zoetis by 48.0% in the fourth quarter. MML Investors Services LLC now owns 12,903 shares of the company’s stock valued at $930,000 after buying an additional 4,186 shares in the last quarter. AXA increased its holdings in Zoetis by 2.6% in the fourth quarter. AXA now owns 258,684 shares of the company’s stock valued at $18,636,000 after buying an additional 6,443 shares in the last quarter. Finally, Bowen Hanes & Co. Inc. increased its holdings in Zoetis by 19.1% in the fourth quarter. Bowen Hanes & Co. Inc. now owns 383,742 shares of the company’s stock valued at $27,645,000 after buying an additional 61,480 shares in the last quarter. 92.45% of the stock is owned by institutional investors.
A number of research analysts have weighed in on ZTS shares. Zacks Investment Research cut shares of Zoetis from a “hold” rating to a “sell” rating and set a $83.00 price objective for the company. in a report on Saturday, January 13th. Citigroup raised shares of Zoetis from a “neutral” rating to a “buy” rating and set a $85.00 target price for the company in a research note on Thursday, January 4th. BMO Capital Markets reissued a “hold” rating on shares of Zoetis in a research note on Monday, January 8th. Cowen set a $80.00 target price on shares of Zoetis and gave the stock a “buy” rating in a research note on Friday, November 17th. Finally, Morgan Stanley raised shares of Zoetis from an “equal weight” rating to an “overweight” rating and set a $80.00 target price for the company in a research note on Wednesday, November 29th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and fourteen have issued a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $80.28.
Zoetis Inc (NYSE:ZTS) opened at $84.41 on Tuesday. The firm has a market cap of $41,130.00, a PE ratio of 38.72, a P/E/G ratio of 1.90 and a beta of 0.97. Zoetis Inc has a 52-week low of $52.25 and a 52-week high of $85.05. The company has a debt-to-equity ratio of 2.77, a quick ratio of 2.55 and a current ratio of 3.85.
Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, February 15th. The company reported $0.69 earnings per share for the quarter, topping analysts’ consensus estimates of $0.66 by $0.03. The firm had revenue of $1.46 billion for the quarter, compared to analyst estimates of $1.40 billion. Zoetis had a net margin of 16.28% and a return on equity of 65.96%. Zoetis’s quarterly revenue was up 14.3% on a year-over-year basis. During the same period in the previous year, the business posted $0.47 earnings per share. analysts anticipate that Zoetis Inc will post 3.04 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, June 1st. Investors of record on Friday, April 20th will be given a dividend of $0.126 per share. The ex-dividend date is Thursday, April 19th. This represents a $0.50 dividend on an annualized basis and a yield of 0.60%. Zoetis’s payout ratio is presently 22.94%.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.